Aura Marroquin

TL;DR: Protection from diabetes in the troglitazone group was closely related to the degree of reduction in endogenous insulin requirements 3 months after randomization and persisted 8 months after study medications were stopped, and was associated with preservation of beta-cell compensation for insulin resistance.

TL;DR: Findings support a class effect of thiazolidinedione drugs to enhance insulin sensitivity, reduce insulin secretory demands, and preserve pancreatic beta-cell function, all in association with a relatively low rate of type 2 diabetes, in Hispanic women with prior gestational diabetes.

TL;DR: The predominant response of pancreatic beta-cells to improved insulin sensitivity in women at high risk for type 2 diabetes was a reduction in insulin release to maintain nearly constant glucose tolerance.

TL;DR: Troglitazone improved whole-body insulin sensitivity and lowered circulating insulin concentrations in women with prior GDM who are at very high risk for NIDDM, and the greatest improvement occurred in the women who had the highest diastolic blood pressures and the best IVGTT insulin responses during baseline testing.

TL;DR: Among young Hispanic women at high risk for type 2 diabetes, the Pro12Ala variant of the PPAR-gamma receptor gene did not explain the failure of approximately 1/3 of subjects to increase their insulin sensitivity when placed on troglitazone at a dose of 400 mg/day.